{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006954",
      "entity_text" : "inflammation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q96RI1",
      "entity_text" : "bile acid receptor",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Moreover, bile acid receptor GP-BAR1 (TGR5) expression has been shown to be increased in rodent models of colitis and Crohn 's disease; and the treatment of a murine model of non alcoholic fatty liver disease with a dual bile acid FXR / TGR5 receptor agonist was shown to decrease intrahepatic inflammation and altered the immune phenotype of monocytes.",
  "reading_complete" : "2020-08-03T16:26:17Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:25:14Z",
  "trigger" : "decrease",
  "evidence" : [ "bile acid receptor GP-BAR1 (TGR5) expression has been shown to be increased in rodent models of colitis and Crohn's disease              ; and the treatment of a murine model of non-alcoholic fatty liver disease with a dual bile acid FXR/TGR5 receptor agonist was shown to decrease intrahepatic inflammation" ],
  "pmc_id" : "4501647",
  "score" : 0
}